España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Axsome Therapeutics
AXSM
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$96.18
4.25
4.62%
At close: -
$96.18
0.00
0.00%
After Hours: 5:17 PM EDT
Get Report
Comment
Axsome Therapeutics (AXSM) Forecast
News
Earnings
Axsome Therapeutics (AXSM) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Axsome Therapeutics (NASDAQ:AXSM) Stock
Axsome Therapeutics Stock (NASDAQ: AXSM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 21, 2025
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
12 Analysts Have This To Say About Axsome Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Monday, January 13, 2025
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Truist Securities Maintains Buy on Axsome The...
Benzinga Newsdesk
Axsome Therapeutics Announced Preliminary Net...
Benzinga Newsdesk
Monday, January 06, 2025
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Tuesday, December 31, 2024
Mizuho Maintains Outperform on Axsome Therape...
Benzinga Newsdesk
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Vandana Singh
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Monday, December 30, 2024
Smart Money Is Betting Big In AXSM Options
Benzinga Insights
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Benzinga Insights
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
Axsome Completes Phase 3 Trials for AXS-05 in...
Benzinga Newsdesk
Thursday, December 12, 2024
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk
Wednesday, November 27, 2024
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Vandana Singh
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Tuesday, November 26, 2024
Axsome Therapeutics Reveals AXS-12 Meets Prim...
Benzinga Newsdesk
Monday, November 25, 2024
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Wednesday, November 13, 2024
Baird Maintains Outperform on Axsome Therapeu...
Benzinga Newsdesk
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Tuesday, November 12, 2024
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics
Benzinga Insights
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Axsome Says Current Cash Is Sufficient To Fun...
Benzinga Newsdesk
Axsome Therapeutics Q3 Sales $104.76M Beat $9...
Benzinga Newsdesk
Earnings Scheduled For November 12, 2024
Benzinga Insights
Friday, November 08, 2024
Axsome Therapeutics Reveals Eight Presentatio...
Benzinga Newsdesk
Friday, October 04, 2024
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Benzinga Insights
RBC Capital Maintains Outperform on Axsome Th...
Benzinga Newsdesk
Tuesday, September 24, 2024
Axsome Therapeutics Announced Seven Presentat...
Benzinga Newsdesk
Friday, September 20, 2024
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk
Monday, September 09, 2024
What Analysts Are Saying About Axsome Therapeutics Stock
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk
Friday, September 06, 2024
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
Zacks
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk
Thursday, September 05, 2024
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Wednesday, September 04, 2024
Axsome Therapeutics shares are trading after ...
Benzinga Newsdesk
Axsome Therapeutics Says FDA Has Acknowledged...
Benzinga Newsdesk
Tuesday, September 03, 2024
Wells Fargo Initiates Coverage On Axsome Ther...
Benzinga Newsdesk
Thursday, August 22, 2024
Unveiling 14 Analyst Insights On Axsome Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Wednesday, August 21, 2024
Axsome Therapeutics Reaches Agreement With Sa...
Benzinga Newsdesk
Thursday, August 15, 2024
Axsome Banks on Auvelity & Sunosi to Fuel Growth
Zacks
Tuesday, August 06, 2024
UBS Maintains Buy on Axsome Therapeutics, Low...
Benzinga Newsdesk
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
